Bill Cameron profile picture

Contact Information

Bill Cameron, MD, FRCPC, FACP
613-737-8923
bcameron@ohri.ca

Executive Assistant: Natasha Filoso-Timpson
nfiloso@ohri.ca

Bill Cameron

Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Medical Director, Clinical Research
Ottawa Hospital Research Institute

Research Interests

Dr. Bill Cameron’s research interest includes infectious disease treatment and prevention in developing countries and in Canada. He is known for his work in the study of sexually transmitted diseases and HIV/AIDS. He has sustained a productive and well-funded clinical and linked laboratory research career, with a number of seminal and first tier contributions in pharmacotherapies and vaccine development. He is a widely respected physician, researcher and teacher in his field.

Brief Biography

Dr. Bill Cameron is Medical Director for Clinical Research at the Ottawa Hospital Research Institute, Senior Scientist for the Clinical Epidemiology Program at the Ottawa Hospital Research Institute, Professor for the Faculty of Medicine at The University of Ottawa, and physician for the Division of Infectious Diseases at The Ottawa Hospital. He has practiced general infectious disease medicine at The Ottawa Hospital for the last 25 years. In the past twenty years or more, Dr. Cameron’s work has made substantial impact in HIV epidemiology and therapeutics.

Selected Publications

Cameron DW, JN Simonsen, LJ D'Costa, AR Ronald, GM Maitha, MN Gakinya, M Cheang, JO Ndinya-Achola, P Piot, RC Brunham and FA Plummer. Female to Male Transmission of Human Immunodeficiency Virus Type 1: Risk Factors for Seroconversion in Men. Lancet 19;2 Aug. 1989, 8660(ii):403-407.

Nightingale SD, DW Cameron, FM Gordin, PM Sullam, DL Cohn, RE Chaisson, LJ Eron, PD Sparti, B Bihari, DL Kaufman, JJ Stern, DD Pearce, WG Weinberg, A LaMarca and FP Siegal. Two Placebo Controlled Trials of Rifabutin Prophylaxis against Mycobacterium Avium Complex Infection in AIDS Patients. N Engl J Med 1993 Sep 16; 392(12):828-33.

Desjardins M, LG Filion, S Robertson, L Kobylinski and DW Cameron. Evaluation of Humoral and Cell Mediated Inducible Immunity to Haemophilus ducreyi in an Animal Model of Chancroid. Infect Immun. 64(5): 1778-88, 1996

Sahai, J. K Gallicano, L Swick, S Tailor, G Garger, I Seguin, L Oliveras, S Walker, A Rachlis, DW Cameron. Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection. Ann Int Med 127(4): 289-93, 1997 PMID: 9265429

Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Potthoff A, Leonard J, and The Advanced HIV Disease Ritonavir Study Group. Randomised Placebo-Controlled Clinical Trial of Ritonavir in Advanced HIV Disease. Lancet 351(9102):543-9, 1998

Garnett GP, Bartley LM, Cameron DW*, Anderson RM. "Both a 'Magic Bullet' and Good Aim are Required to Link Public Health Interests and Health Care Needs in HIV Infection." Nat Med. 2000 Mar;6(3):261-2.

Van Heeswijk RPG, Y Khaliq, KD Gallicano, M Bourbeau, I Seguin, EJ Phillips, DW Cameron. The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum. Clin Pharm & Ther 76(6):588-97, 2004 DOI:10.1016/j.clpt.2004.08.011. PMID: 15592330.

Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves HBV vaccine seroprotection in antiretroviral treated HIV-infected adults. AIDS 19(14):1473-9, 2005 PMID: 16135900.

Cameron DW, da Silva BA, Arriba JR, Myers RA, Bellow NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ. A 96 week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 198:234-240, 2008 DOI: 10.1086/589622

Voduc N, la Porte C, Tessier C, Mallick R, Cameron DW. Effect of resveratrol on exercise capacity: A randomized placebo-controlled cross-over pilot study. Applied Physiology, Nutrition, and Metabolism, 2014 Apr 30:1-5. [Epub ahead of print], 10.1139/apnm-2013-0547